home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605d.zip
/
M9651100.TXT
< prev
next >
Wrap
Text File
|
1996-03-30
|
2KB
|
28 lines
Document 1100
DOCN M9651100
TI Primary central nervous system lymphoma.
DT 9505
AU Freilich RJ; DeAngelis LM; Department of Neurology, Memorial
Sloan-Kettering Cancer Center,; New York, New York, USA.
SO Neurol Clin. 1995 Nov;13(4):901-14. Unique Identifier : AIDSLINE
MED/96157925
AB The rising incidence of PCNSL has allowed a greater understanding of the
clinical features and behavior of this once rare tumor. Factors such as
dissemination of tumor within the central nervous system, the presence
of tumor behind an intact blood-brain barrier, as well as leptomeningeal
and ocular involvement must be considered in the design of treatment
protocols for this disease. The addition of chemotherapy has made a
significant impact on the treatment of PCNSL, but the prognosis of PCNSL
remains worse than for comparable systemic non-Hodgkin's lymphomas. With
continued development of chemotherapy regimens, the hope is for improved
survival without the need for potentially neurotoxic radiation therapy.
DE Brain/PATHOLOGY Brain Neoplasms/PATHOLOGY/*THERAPY Chemotherapy,
Adjuvant Combined Modality Therapy Cranial Irradiation Human
Lymphoma, AIDS-Related/PATHOLOGY/*THERAPY Lymphoma,
Non-Hodgkin's/PATHOLOGY/*THERAPY Prognosis JOURNAL ARTICLE REVIEW
REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).